BioLum Sciences

BioLum Sciences is a private, preclinical-stage company developing a proprietary chemiluminescence platform for sensitive biomarker detection in drug discovery and diagnostics. Its core business involves providing custom assay development and high-throughput screening services to pharmaceutical partners, while also building a pipeline of its own chemiluminescence kits aimed at eventual translation into in vitro diagnostics. The company targets major disease areas including cardiovascular, neurologic, respiratory, and pain & inflammation disorders, positioning itself at the intersection of precision medicine and proactive healthcare.

Novel chemiluminescence technology for superior detection of reactive oxygen, nitrogen, and sulfur species (RONSS). Claims higher sensitivity and selectivity than gold-standard assays (Griess & DAF) by mitigating background autofluorescence.

BioLum competes with large diagnostic companies (e.g., Roche, Abbott) and numerous life science tool suppliers (e.g., Cayman Chemical, Abcam, Thermo Fisher) that offer biomarker detection assays. Its claimed technical superiority in RONSS detection is its primary differentiator, but it must compete on scale, brand recognition, and commercial reach.